VRTX Short Volume
Vertex Pharmaceuticals Incorporated (VRTX) operates in the Healthcare sector, specifically the Biotechnology industry, with a market capitalization near $124.70B, listed on NASDAQ, employing roughly 6,100 people, carrying a beta of 0.31 to the broader market. Vertex Pharmaceuticals Incorporated is a leading biotechnology firm primarily focused on the discovery, advancement, and marketing of innovative treatments, particularly for cystic fibrosis (CF). Led by Reshma Kewalramani, public since 1991-07-24.
Short volume measures the number of shares sold short on a given day as reported by FINRA. Tracking short volume relative to total volume helps identify unusual bearish sentiment or short-squeeze potential.
- Latest Date
- 2026-06-30
- Short Volume
- 296.8K
- Total Volume
- 650.0K
- Short %
- 45.65%
- 30-Day Avg Short %
- 46.27%
Showing 30 days of FINRA short volume data for Vertex Pharmaceuticals Incorporated.
Learn how short volume is reported and how to read the data →
Frequently asked VRTX short volume questions
- What is the daily VRTX short volume?
- As of Jun 30, 2026, Vertex Pharmaceuticals Incorporated (VRTX) short volume is 296.8K shares against 650.0K total reported volume, or 45.65% short-side. Short volume measures shares sold short during the day; it is flow, not inventory.
- How is VRTX short volume reported?
- FINRA publishes the Daily Short Sale Volume File for trades reported to FINRA TRFs and the FINRA/Nasdaq ADF on a T+1 basis. The headline figure is the count of shares that printed at the short-sale or short-exempt tick across all reporting venues for the symbol; each exchange separately publishes its own daily short-sale data file.
- What does VRTX short volume tell options traders?
- Daily short-sale flow is one input that helps disambiguate dealer-hedging activity from directional bear flow when the chain shows fresh customer call inventory. It is not a clean MM-only proxy: the headline number mixes directional shorting, options-MM delta-hedging, ETF-creation arbitrage, and convertible-arb hedging. Cross-check against gamma-exposure and OI changes for a cleaner read.